Boost Pharma
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $10.8Mattributed |
|---|---|
| Latest round | seed, $3.2M, 2025-11-01attributed |
| Founded | 2018 |
| Headquarters | Stockholm, Sweden |
| Industry | biotech |
| Stage | series-a |
| Website | boostpharma.se |
Clinical-stage biotech developing BT-101, a mesenchymal stem-cell therapy for the genetic bone disease Osteogenesis Imperfecta. Targets children with brittle-bone disease who face frequent fractures and deformities. Two-year Phase 1/2 follow-up showed roughly 78% fewer fractures versus baseline, with origins in Karolinska Institutet research.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-11-01 | seed | $3.2M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $3.2M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $10.8M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | boostpharma.se, read 2026-05-07 |
| Description | self-reported | boostpharma.se, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.